Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw unusually large options trading on Thursday. Traders acquired 42,588 put options on the company. This is an increase of approximately 240% compared to the typical volume of 12,513 put options.
Analysts Set New Price Targets
GILD has been the topic of a number of recent analyst reports. Cantor Fitzgerald decreased their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Mizuho reduced their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a report on Wednesday. Royal Bank of Canada reduced their price target on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 14th. Finally, UBS Group cut their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $84.57.
View Our Latest Research Report on GILD
Insider Transactions at Gilead Sciences
Institutional Investors Weigh In On Gilead Sciences
Several institutional investors have recently bought and sold shares of GILD. Norges Bank bought a new stake in Gilead Sciences during the fourth quarter worth $1,301,624,000. The Manufacturers Life Insurance Company grew its holdings in Gilead Sciences by 78.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 7,632,000 shares of the biopharmaceutical company’s stock worth $618,268,000 after buying an additional 3,362,505 shares in the last quarter. Clearbridge Investments LLC grew its holdings in Gilead Sciences by 179.0% during the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock worth $340,526,000 after buying an additional 2,915,141 shares in the last quarter. Wellington Management Group LLP grew its holdings in Gilead Sciences by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock worth $1,509,227,000 after buying an additional 2,350,550 shares in the last quarter. Finally, abrdn plc grew its holdings in Gilead Sciences by 89.0% during the fourth quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock worth $304,930,000 after buying an additional 1,772,887 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.
Gilead Sciences Stock Down 2.3 %
Shares of NASDAQ GILD traded down $1.53 during midday trading on Thursday, hitting $65.55. 4,851,889 shares of the stock traded hands, compared to its average volume of 7,281,077. The company has a market cap of $81.61 billion, a PE ratio of 14.98, a P/E/G ratio of 0.96 and a beta of 0.19. Gilead Sciences has a one year low of $65.32 and a one year high of $87.86. The business has a 50 day moving average price of $71.56 and a two-hundred day moving average price of $76.39. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The firm had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.67 EPS. On average, equities analysts predict that Gilead Sciences will post 5.24 EPS for the current year.
Gilead Sciences Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were issued a dividend of $0.77 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.70%. Gilead Sciences’s payout ratio is currently 68.44%.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- How to Use the MarketBeat Excel Dividend Calculator
- Hasbro’s Management Made All the Right Calls This Quarter
- The Most Important Warren Buffett Stock for Investors: His Own
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- The How And Why of Investing in Oil Stocks
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.